Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SkinJect Patch
- Development stage
- Unknown
- Lead developer
- Medicus Pharma
- Modality
- Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Administration
- Transdermal
01
Overview
SkinJect Patch is a novel dissolvable microneedle delivery system designed for the localized treatment of non-melanoma skin cancers, specifically basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Developed by SkinJect Inc., a subsidiary of Medicus Pharma Ltd., the patch features a cellulose-based array of 400 microneedles, each 750 microns in length, which are tip-loaded with the chemotherapeutic agent doxorubicin. Upon application to the skin, the microneedles penetrate the dermis and dissolve within approximately 15 minutes, releasing the drug directly into the tumor site. The therapeutic effect is achieved through a dual mechanism: direct cytotoxicity to cancer cells via DNA intercalation and topoisomerase II inhibition, and the induction of an immunogenic response through the activation of the calreticulin pathway. This localized approach aims to maximize efficacy at the tumor site while minimizing the systemic toxicity typically associated with conventional chemotherapy.
- Brand names
- SkinJect Patch
- Other names
- doxorubicin dissolvable microneedle patch
02
Targets
DNATOP2A (DNA topoisomerase II)CALR (Calreticulin)
Beyond the preview
Go deeper on SkinJect Patch.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SkinJect Patch.